Progressive multifocal leukoencephalopathy in HIV-1 infection

The Lancet Infectious Diseases

Volumn 9, Issue 10, 2009, Pages 625-636

  Cinque, Paola ^a   Koralnik, Igor J ^b   Gerevini, Simonetta ^a   Miro, Jose M ^c   Price, Richard W ^d  

^a SAN RAFFAELE HOSPITAL   (Italy)

^b BETH ISRAEL DEACONESS MEDICAL CENTER   (United States)

^c UNIVERSITY OF BARCELONA   (Spain)

^d UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA INTERFERON; ANTIRETROVIRUS AGENT; BETA INTERFERON; CD4 ANTIGEN; CIDOFOVIR; CYTARABINE; DEXAMETHASONE; GENE PRODUCT; INTERLEUKIN 2; MEFLOQUINE; METHYLPREDNISOLONE; PREDNISONE; SEROTONIN ANTAGONIST; TOPOTECAN; VIRUS DNA; VIRUS RNA;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; BRAIN BIOPSY; CD4 LYMPHOCYTE COUNT; CELLULAR IMMUNITY; CENTRAL NERVOUS SYSTEM; CEREBROSPINAL FLUID; CLINICAL ASSESSMENT; CLINICAL FEATURE; CLINICAL TRIAL; DIFFUSION WEIGHTED IMAGING; DRUG EFFICACY; DRUG MEGADOSE; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; IMMUNOSUPPRESSIVE TREATMENT; JC VIRUS; LUMBAR PUNCTURE; LYMPHOCYTE PROLIFERATION; LYMPHOCYTIC INFILTRATION; NEUROIMAGING; NEUROPATHOLOGY; NONHODGKIN LYMPHOMA; NONHUMAN; NUCLEAR MAGNETIC RESONANCE IMAGING; OLIGODENDROGLIA; OPPORTUNISTIC INFECTION; OUTCOME ASSESSMENT; PRIORITY JOURNAL; PROGRESSIVE MULTIFOCAL LEUKOENCEPHALOPATHY; PROSPECTIVE STUDY; REVIEW; TREATMENT RESPONSE; VIRUS ETIOLOGY; VIRUS IMMUNITY; VIRUS PATHOGENESIS;

CEREBROSPINAL FLUID; HIV INFECTIONS; HUMANS; JC VIRUS; LEUKOENCEPHALOPATHY, PROGRESSIVE MULTIFOCAL;

EID: 70349188237     PISSN: 14733099     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1473-3099(09)70226-9     Document Type: Review

References (112)

1. Richardson Jr. E.P. Progressive multifocal leukoencephalopathy. N Engl J Med 265 (1961) 815-823
2. Garcia-Suarez J., de Miguel D., Krsnik I., Banas H., Arribas I., and Burgaleta C. Changes in the natural history of progressive multifocal leukoencephalopathy in HIV-negative lymphoproliferative disorders: impact of novel therapies. Am J Hematol 80 (2005) 271-281
3. Kappos L., Bates D., Hartung H.P., et al. Natalizumab treatment for multiple sclerosis: recommendations for patient selection and monitoring. Lancet Neurol 6 (2007) 431-441
4. Hartung H.P. New cases of progressive multifocal leukoencephalopathy after treatment with natalizumab. Lancet Neurol 8 (2009) 28-31
5. Molloy E.S., and Calabrese L.H. Therapy: targeted but not trouble-free: efalizumab and PML. Nat Rev Rheumatol 5 (2009) 418-419
6. Carson K.R., Focosi D., Major E.O., et al. Monoclonal antibody-associated progressive multifocal leucoencephalopathy in patients treated with rituximab, natalizumab, and efalizumab: a Review from the Research on Adverse Drug Events and Reports (RADAR) Project. Lancet Oncol 10 (2009) 816-824
7. Petito C.K., Cho E.S., Lemann W., Navia B.A., and Price R.W. Neuropathology of acquired immunodeficiency syndrome (AIDS): an autopsy review. J Neuropathol Exp Neurol 45 (1986) 635-646
8. Lang W., Miklossy J., Deruaz J.P., et al. Neuropathology of the acquired immune deficiency syndrome (AIDS): a report of 135 consecutive autopsy cases from Switzerland. Acta Neuropathol 77 (1989) 379-390
9. Cinque P., Vago L., Dahl H., et al. Polymerase chain reaction on cerebrospinal fluid for diagnosis of virus-associated opportunistic diseases of the central nervous system in HIV-infected patients. AIDS 10 (1996) 951-958
10. d'Arminio Monforte A., Cinque P., Mocroft A., et al. Changing incidence of central nervous system diseases in the EuroSIDA cohort. Ann Neurol 55 (2004) 320-328
11. Grabar S., Lanoy E., Allavena C., et al. Causes of the first AIDS-defining illness and subsequent survival before and after the advent of combined antiretroviral therapy. HIV Med 9 (2008) 246-256
12. Cinque P., Bossolasco S., Brambilla A.M., et al. The effect of highly active antiretroviral therapy-induced immune reconstitution on development and outcome of progressive multifocal leukoencephalopathy: study of 43 cases with review of the literature. J Neurovirol 9 suppl 1 (2003) 73-80
13. Falco V., Olmo M., del Saz S.V., et al. Influence of HAART on the clinical course of HIV-1-infected patients with progressive multifocal leukoencephalopathy: results of an observational multicenter study. J Acquir Immune Defic Syndr 49 (2008) 26-31
14. Clifford D.B., Yiannoutsos C., Glicksman M., et al. HAART improves prognosis in HIV-associated progressive multifocal leukoencephalopathy. Neurology 52 (1999) 623-625
15. Berenguer J., Miralles P., Arrizabalaga J., et al. Clinical course and prognostic factors of progressive multifocal leukoencephalopathy in patients treated with highly active antiretroviral therapy. Clin Infect Dis 36 (2003) 1047-1052
16. Khanna N., Elzi L., Mueller N.J., et al. Incidence and outcome of progressive multifocal leukoencephalopathy over 20 years of the Swiss HIV Cohort Study. Clin Infect Dis 48 (2009) 1459-1466
17. Mocroft A., Sterne J.A., Egger M., et al. Variable impact on mortality of AIDS-defining events diagnosed during combination antiretroviral therapy: not all AIDS-defining conditions are created equal. Clin Infect Dis 48 (2009) 1138-1151
18. Lewden C., May T., Rosenthal E., et al. Changes in causes of death among adults infected by HIV between 2000 and 2005: the "Mortalite 2000 and 2005" surveys (ANRS EN19 and Mortavic). J Acquir Immune Defic Syndr 48 (2008) 590-598
19. Frisque R.J., Bream G.L., and Cannella M.T. Human polyomavirus JC virus genome. J Virol 51 (1984) 458-469
20. Bofill-Mas S., Formiga-Cruz M., Clemente-Casares P., Calafell F., and Girones R. Potential transmission of human polyomaviruses through the gastrointestinal tract after exposure to virions or viral DNA. J Virol 75 (2001) 10290-10299
21. Monaco M.C., Jensen P.N., Hou J., Durham L.C., and Major E.O. Detection of JC virus DNA in human tonsil tissue: evidence for site of initial viral infection. J Virol 72 (1998) 9918-9923
22. Sabath B.F., and Major E.O. Traffic of JC virus from sites of initial infection to the brain: the path to progressive multifocal leukoencephalopathy. J Infect Dis 186 suppl 2 (2002) S180-S186
23. Knowles W.A., Pipkin P., Andrews N., et al. Population-based study of antibody to the human polyomaviruses BKV and JCV and the simian polyomavirus SV40. J Med Virol 71 (2003) 115-123
24. Kean J.M., Rao S., Wang M., and Garcea R.L. Seroepidemiology of human polyomaviruses. PLoS Pathog 5 (2009) e1000363
25. Hamilton R.S., Gravell M., and Major E.O. Comparison of antibody titers determined by hemagglutination inhibition and enzyme immunoassay for JC virus and BK virus. J Clin Microbiol 38 (2000) 105-109
26. Egli A., Infanti L., Dumoulin A., et al. Prevalence of polyomavirus BK and JC infection and replication in 400 healthy blood donors. J Infect Dis 199 (2009) 837-846
27. Markowitz R.B., Thompson H.C., Mueller J.F., Cohen J.A., and Dynan W.S. Incidence of BK virus and JC virus viruria in human immunodeficiency virus-infected and -uninfected subjects. J Infect Dis 167 (1993) 13-20
28. Lednicky J.A., Vilchez R.A., Keitel W.A., et al. Polyomavirus JCV excretion and genotype analysis in HIV-infected patients receiving highly active antiretroviral therapy. AIDS 17 (2003) 801-807
29. Tan C.S., Dezube B.J., Bhargava P., et al. Detection of JC virus DNA and proteins in the bone marrow of HIV-positive and HIV-negative patients: implications for viral latency and neurotropic transformation. J Infect Dis 199 (2009) 881-888
30. White III F.A., Ishaq M., Stoner G.L., and Frisque R.J. JC virus DNA is present in many human brain samples from patients without progressive multifocal leukoencephalopathy. J Virol 66 (1992) 5726-5734
31. Perez-Liz G., Del Valle L., Gentilella A., Croul S., and Khalili K. Detection of JC virus DNA fragments but not proteins in normal brain tissue. Ann Neurol 64 (2008) 379-387
32. Vago L., Cinque P., Sala E., et al. JCV-DNA and BKV-DNA in the CNS tissue and CSF of AIDS patients and normal subjects: study of 41 cases and review of the literature. J Acquir Immune Defic Syndr 12 (1996) 139-146
33. Procop G.W., Beck R.C., Pettay J.D., et al. JC virus chromogenic in situ hybridization in brain biopsies from patients with and without PML. Diagn Mol Pathol 15 (2006) 70-73
34. Ciappi S., Azzi A., De Santis R., et al. Archetypal and rearranged sequences of human polyomavirus JC transcription control region in peripheral blood leukocytes and in cerebrospinal fluid. J Gen Virol 80 (1999) 1017-1023
35. Fedele C.G., Ciardi M.R., Delia S., et al. Identical rearranged forms of JC polyomavirus transcriptional control region in plasma and cerebrospinal fluid of acquired immunodeficiency syndrome patients with progressive multifocal leukoencephalopathy. J Neurovirol 9 (2003) 551-558
36. Pfister L.A., Letvin N.L., and Koralnik I.J. JC virus regulatory region tandem repeats in plasma and central nervous system isolates correlate with poor clinical outcome in patients with progressive multifocal leukoencephalopathy. J Virol 75 (2001) 5672-5676
37. Gasnault J., Kahraman M., de Goer de Herve M.G., Durali D., Delfraissy J.F., and Taoufik Y. Critical role of JC virus-specific CD4 T-cell responses in preventing progressive multifocal leukoencephalopathy. AIDS 17 (2003) 1443-1449
38. Du Pasquier R.A., Schmitz J.E., Jean-Jacques J., et al. Detection of JC virus-specific cytotoxic T lymphocytes in healthy individuals. J Virol 78 (2004) 10206-10210
39. Price R.W., Nielsen S., Horten B., Rubino M., Padgett B., and Walker D. Progressive multifocal leukoencephalopathy: a burnt-out case. Ann Neurol 13 (1983) 485-490
40. Du Pasquier R.A., Kuroda M.J., Zheng Y., Jean-Jacques J., Letvin N.L., and Koralnik I.J. A prospective study demonstrates an association between JC virus-specific cytotoxic T lymphocytes and the early control of progressive multifocal leukoencephalopathy. Brain 127 (2004) 1970-1978
41. Khanna N., Wolbers M., Mueller N.J., et al. JC virus-specific immune responses in human immunodeficiency virus type 1 patients with progressive multifocal leukoencephalopathy. J Virol 83 (2009) 4404-4411
42. Giudici B., Vaz B., Bossolasco S., et al. Highly active antiretroviral therapy and progressive multifocal leukoencephalopathy: effects on cerebrospinal fluid markers of JC virus replication and immune response. Clin Infect Dis 30 (2000) 95-99
43. Du Pasquier R.A., Autissier P., Zheng Y., Jean-Jacques J., and Koralnik I.J. Presence of JC virus-specific CTL in the cerebrospinal fluid of PML patients: rationale for immune-based therapeutic strategies. AIDS 19 (2005) 2069-2076
44. Bernal-Cano F., Joseph J.T., and Koralnik I.J. Spinal cord lesions of progressive multifocal leukoencephalopathy in an AIDS patient. J Neurovirol 13 (2007) 474-476
45. Wuthrich C., Cheng Y.M., Joseph J.T., et al. Frequent infection of cerebellar granule cell neurons by polyomavirus JC in progressive multifocal leukoencephalopathy. J Neuropathol Exp Neurol 68 (2009) 15-25
46. Huang D., Cossoy M., Li M., et al. Inflammatory progressive multifocal leukoencephalopathy in human immunodeficiency virus-negative patients. Ann Neurol 62 (2007) 34-39
47. Miralles P., Berenguer J., Lacruz C., et al. Inflammatory reactions in progressive multifocal leukoencephalopathy after highly active antiretroviral therapy. AIDS 15 (2001) 1900-1902
48. Vendrely A., Bienvenu B., Gasnault J., Thiebault J.B., Salmon D., and Gray F. Fulminant inflammatory leukoencephalopathy associated with HAART-induced immune restoration in AIDS-related progressive multifocal leukoencephalopathy. Acta Neuropathol 109 (2005) 449-455
49. Martinez J.V., Mazziotti J.V., Efron E.D., et al. Immune reconstitution inflammatory syndrome associated with PML in AIDS: a treatable disorder. Neurology 67 (2006) 1692-1694
50. Lima M.A., Drislane F.W., and Koralnik I.J. Seizures and their outcome in progressive multifocal leukoencephalopathy. Neurology 66 (2006) 262-264
51. Berger J.R., Pall L., Lanska D., and Whiteman M. Progressive multifocal leukoencephalopathy in patients with HIV infection. J Neurovirol 4 (1998) 59-68
52. Zunt J.R., Tu R.K., Anderson D.M., Copass M.C., and Marra C.M. Progressive multifocal leukoencephalopathy presenting as human immunodeficiency virus type 1 (HIV)-associated dementia. Neurology 49 (1997) 263-265
53. Berger J.R., Levy R.M., Flomenhoft D., and Dobbs M. Predictive factors for prolonged survival in acquired immunodeficiency syndrome-associated progressive multifocal leukoencephalopathy. Ann Neurol 44 (1998) 341-349
54. Cinque P., Koralnik I.J., and Clifford D.B. The evolving face of human immunodeficiency virus-related progressive multifocal leukoencephalopathy: defining a consensus terminology. J Neurovirol 9 suppl 1 (2003) 88-92
55. Portegies P., Solod L., Cinque P., et al. Guidelines for the diagnosis and management of neurological complications of HIV infection. Eur J Neurol 11 (2004) 297-304
56. Kaplan J.E., Benson C., Holmes K.H., Brooks J.T., Pau A., and Masur H. Guidelines for prevention and treatment of opportunistic infections in HIV-infected adults and adolescents: recommendations from CDC, the National Institutes of Health, and the HIV Medicine Association of the Infectious Diseases Society of America. MMWR Recomm Rep 58 (2009) 1-207
57. Manzardo C., Del Mar Ortega M., Sued O., Garcia F., Moreno A., and Miro J.M. Central nervous system opportunistic infections in developed countries in the highly active antiretroviral therapy era. J Neurovirol 11 suppl 3 (2005) 72-82
58. Skiest D.J. Focal neurological disease in patients with acquired immunodeficiency syndrome. Clin Infect Dis 34 (2002) 103-115
59. Post M.J., Yiannoutsos C., Simpson D., et al. Progressive multifocal leukoencephalopathy in AIDS: are there any MR findings useful to patient management and predictive of patient survival?. AJNR Am J Neuroradiol 20 (1999) 1896-1906
60. Thurnher M.M., Post M.J., Rieger A., Kleibl-Popov C., Loewe C., and Schindler E. Initial and follow-up MR imaging findings in AIDS-related progressive multifocal leukoencephalopathy treated with highly active antiretroviral therapy. AJNR Am J Neuroradiol 22 (2001) 977-984
61. Mader I., Herrlinger U., Klose U., Schmidt F., and Kuker W. Progressive multifocal leukoencephalopathy: analysis of lesion development with diffusion-weighted MRI. Neuroradiology 45 (2003) 717-721
62. Bergui M., Bradac G.B., Oguz K.K., et al. Progressive multifocal leukoencephalopathy: diffusion-weighted imaging and pathological correlations. Neuroradiology 46 (2004) 22-25
63. Usiskin S.I., Bainbridge A., Miller R.F., and Jager H.R. Progressive multifocal leukoencephalopathy: serial high-b-value diffusion-weighted MR imaging and apparent diffusion coefficient measurements to assess response to highly active antiretroviral therapy. AJNR Am J Neuroradiol 28 (2007) 285-286
64. Chang L., Ernst T., Tornatore C., et al. Metabolite abnormalities in progressive multifocal leukoencephalopathy by proton magnetic resonance spectroscopy. Neurology 48 (1997) 836-845
65. Simone I.L., Federico F., Tortorella C., et al. Localised 1H-MR spectroscopy for metabolic characterisation of diffuse and focal brain lesions in patients infected with HIV. J Neurol Neurosurg Psychiatry 64 (1998) 516-523
66. Cinque P., Scarpellini P., Vago L., Linde A., and Lazzarin A. Diagnosis of central nervous system complications in HIV-infected patients: cerebrospinal fluid analysis by the polymerase chain reaction. AIDS 11 (1997) 1-17
67. Marzocchetti A., Di Giambenedetto S., Cingolani A., Ammassari A., Cauda R., and De Luca A. Reduced rate of diagnostic positive detection of JC virus DNA in cerebrospinal fluid in cases of suspected progressive multifocal leukoencephalopathy in the era of potent antiretroviral therapy. J Clin Microbiol 43 (2005) 4175-4177
68. Yiannoutsos C.T., Major E.O., Curfman B., et al. Relation of JC virus DNA in the cerebrospinal fluid to survival in acquired immunodeficiency syndrome patients with biopsy-proven progressive multifocal leukoencephalopathy. Ann Neurol 45 (1999) 816-821
69. Bossolasco S., Calori G., Moretti F., et al. Prognostic significance of JC virus DNA levels in cerebrospinal fluid of patients with HIV-associated progressive multifocal leukoencephalopathy. Clin Infect Dis 40 (2005) 738-744
70. De Luca A., Ammassari A., Pezzotti P., et al. Cidofovir in addition to antiretroviral treatment is not effective for AIDS-associated progressive multifocal leukoencephalopathy: a multicohort analysis. AIDS 22 (2008) 1759-1767
71. Jochum W., Weber T., Frye S., Hunsmann G., Luke W., and Aguzzi A. Detection of JC virus by anti-VP1 immunohistochemistry in brains with progressive multifocal leukoencephalopathy. Acta Neuropathol 94 (1997) 226-231
72. Tornatore C., Berger J.R., Houff S.A., et al. Detection of JC virus DNA in peripheral lymphocytes from patients with and without progressive multifocal leukoencephalopathy. Ann Neurol 31 (1992) 454-462
73. Koralnik I.J., Boden D., Mai V.X., Lord C.I., and Letvin N.L. JC virus DNA load in patients with and without progressive multifocal leukoencephalopathy. Neurology 52 (1999) 253-260
74. Andreoletti L., Lescieux A., Lambert V., et al. Semiquantitative detection of JCV-DNA in peripheral blood leukocytes from HIV-1-infected patients with or without progressive multifocal leukoencephalopathy. J Med Virol 66 (2002) 1-7
75. Dubois V., Moret H., Lafon M.E., et al. Prevalence of JC virus viraemia in HIV-infected patients with or without neurological disorders: a prospective study. J Neurovirol 4 (1998) 539-544
76. Shah K.V., Daniel R.W., Strickler H.D., and Goedert J.J. Investigation of human urine for genomic sequences of the primate polyomaviruses simian virus 40, BK virus, and JC virus. J Infect Dis 176 (1997) 1618-1621
77. Knowles W.A., Pillay D., Johnson M.A., Hand J.F., and Brown D.W. Prevalence of long-term BK and JC excretion in HIV-infected adults and lack of correlation with serological markers. J Med Virol 59 (1999) 474-479
78. Weber T., Trebst C., Frye S., et al. Analysis of the systemic and intrathecal humoral immune response in progressive multifocal leukoencephalopathy. J Infect Dis 176 (1997) 250-254
79. Weber F., Goldmann C., Kramer M., et al. Cellular and humoral immune response in progressive multifocal leukoencephalopathy. Ann Neurol 49 (2001) 636-642
80. Binggeli S., Egli A., Schaub S., et al. Polyomavirus BK-specific cellular immune response to VP1 and large T-antigen in kidney transplant recipients. Am J Transplant 7 (2007) 1131-1139
81. Tan K., Roda R., Ostrow L., McArthur J., and Nath A. PML-IRIS in patients with HIV infection: clinical manifestations and treatment with steroids. Neurology 72 (2009) 1458-1464
82. Shelburne III S.A., Hamill R.J., Rodriguez-Barradas M.C., et al. Immune reconstitution inflammatory syndrome: emergence of a unique syndrome during highly active antiretroviral therapy. Medicine 81 (2002) 213-227
83. French M.A., Price P., and Stone S.F. Immune restoration disease after antiretroviral therapy. AIDS 18 (2004) 1615-1627
84. French M.A. HIV/AIDS: immune reconstitution inflammatory syndrome: a reappraisal. Clin Infect Dis 48 (2009) 101-107
85. Hall C.D., Dafni U., Simpson D., et al. Failure of cytarabine in progressive multifocal leukoencephalopathy associated with human immunodeficiency virus infection. N Engl J Med 338 (1998) 1345-1351
86. Hou J., and Major E.O. The efficacy of nucleoside analogs against JC virus multiplication in a persistently infected human fetal brain cell line. J Neurovirol 4 (1998) 451-456
87. Andrei G., Snoeck R., Vandeputte M., and De Clercq E. Activities of various compounds against murine and primate polyomaviruses. Antimicrob Agents Chemother 41 (1997) 587-593
88. Royal III W., Dupont B., McGuire D., et al. Topotecan in the treatment of acquired immunodeficiency syndrome-related progressive multifocal leukoencephalopathy. J Neurovirol 9 (2003) 411-419
89. Kerr D.A., Chang C.F., Gordon J., Bjornsti M.A., and Khalili K. Inhibition of human neurotropic virus (JCV) DNA replication in glial cells by camptothecin. Virology 196 (1993) 612-618
90. Geschwind M.D., Skolasky R.I., Royal W.S., and McArthur J.C. The relative contributions of HAART and alpha-interferon for therapy of progressive multifocal leukoencephalopathy in AIDS. J Neurovirol 7 (2001) 353-357
91. Tashiro K., Doi S., Moriwaka F., Maruo Y., and Nomura M. Progressive multifocal leucoencephalopathy with magnetic resonance imaging verification and therapeutic trials with interferon. J Neurol 234 (1987) 427-429
92. Nath A., Venkataramana A., Reich D.S., Cortese I., and Major E.O. Progression of progressive multifocal leukoencephalopathy despite treatment with beta-interferon. Neurology 66 (2006) 149-150
93. Lima M.A., Auriel E., Wuthrich C., Borenstein N.M., and Koralnik I.J. Progressive multifocal leukoencephalopathy as a complication of hepatitis C virus treatment in an HIV-negative patient. Clin Infect Dis 41 (2005) 417-419
94. Vulliemoz S., Lurati-Ruiz F., Borruat F.X., et al. Favourable outcome of progressive multifocal leucoencephalopathy in two patients with dermatomyositis. J Neurol Neurosurg Psychiatry 77 (2006) 1079-1082
95. Focosi D., Fazzi R., Montanaro D., Emdin M., and Petrini M. Progressive multifocal leukoencephalopathy in a haploidentical stem cell transplant recipient: a clinical, neuroradiological and virological response after treatment with risperidone. Antiviral Res 74 (2007) 156-158
96. Verma S., Cikurel K., Koralnik I.J., et al. Mirtazapine in progressive multifocal leukoencephalopathy associated with polycythemia vera. J Infect Dis 196 (2007) 709-711
97. Cettomai D., and McArthur J.C. Mirtazapine use in human immunodeficiency virus-infected patients with progressive multifocal leukoencephalopathy. Arch Neurol 66 (2009) 255-258
98. Elphick G.F., Querbes W., Jordan J.A., et al. The human polyomavirus, JCV, uses serotonin receptors to infect cells. Science 306 (2004) 1380-1383
99. Przepiorka D., Jaeckle K.A., Birdwell R.R., et al. Successful treatment of progressive multifocal leukoencephalopathy with low-dose interleukin-2. Bone Marrow Transplant 20 (1997) 983-987
100. Buckanovich R.J., Liu G., Stricker C., et al. Nonmyeloablative allogeneic stem cell transplantation for refractory Hodgkin's lymphoma complicated by interleukin-2 responsive progressive multifocal leukoencephalopathy. Ann Hematol 81 (2002) 410-413
101. Kunschner L., and Scott T.F. Sustained recovery of progressive multifocal leukoencephalopathy after treatment with IL-2. Neurology 65 (2005) 1510
102. Brickelmaier M., Lugovskoy A., Kartikeyan R., et al. Identification and characterization of mefloquine efficacy against JC virus in vitro. Antimicrob Agents Chemother 53 (2009) 1840-1849
103. US NIH. Study to explore the effect of mefloquine in subjects with progressive multifocal leukoencephalopathy (PML). http://clinicaltrials.gov/show/NCT00746941?order=17 (accessed Aug 19, 2009).
104. Gasnault J., Taoufik Y., Goujard C., et al. Prolonged survival without neurological improvement in patients with AIDS-related progressive multifocal leukoencephalopathy on potent combined antiretroviral therapy. J Neurovirol 5 (1999) 421-429
105. Gasnault J, Chavez HH, Dorofeev E, et al. Acceleration of immune recovery on intensified art improves survival in patients with aids-related progressive multifocal leukoencephalopathy: preliminary reports of the ANRS 125 trial. 14th Conference on Retroviruses and Opportunistic Infections; Los Angeles, CA, USA; Feb 25-27, 2007. Abstract 379.
106. Letendre S., Marquie-Beck J., Capparelli E., et al. Validation of the CNS penetration-effectiveness rank for quantifying antiretroviral penetration into the central nervous system. Arch Neurol 65 (2008) 65-70
107. Gasnault J, Lanoy E, Bentata M, Guiguet M, Costagliola D. Intracerebral penetrating ART are more efficient on survival of HIV+ patients with progressive multifocal leucoencephalopathy (ANRS CO4-FHDH). 15th Conference on Retroviruses and Opportunistic Infections; Boston, MA, USA; Feb 3-6, 2008. Abstract 385.
108. Tada H., Rappaport J., Lashgari M., Amini S., Wong-Staal F., and Khalili K. Trans-activation of the JC virus late promoter by the tat protein of type 1 human immunodeficiency virus in glial cells. Proc Natl Acad Sci USA 87 (1990) 3479-3483
109. Berger J.R., Chauhan A., Galey D., and Nath A. Epidemiological evidence and molecular basis of interactions between HIV and JC virus. J Neurovirol 7 (2001) 329-338
110. Sinclair E., Ronquillo R., Lollo N., et al. Antiretroviral treatment effect on immune activation reduces cerebrospinal fluid HIV-1 infection. J Acquir Immune Defic Syndr 47 (2008) 544-552
111. Katz-Brull R., Lenkinski R.E., Du Pasquier R.A., and Koralnik I.J. Elevation of myoinositol is associated with disease containment in progressive multifocal leukoencephalopathy. Neurology 63 (2004) 897-900
112. Taoufik Y., Gasnault J., Karaterki A., et al. Prognostic value of JC virus load in cerebrospinal fluid of patients with progressive multifocal leukoencephalopathy. J Infect Dis 178 (1998) 1816-1820